Target intelligence / Profile preview

Transient receptor potential canonical 7 channel (TRPC7)

Target: TRPC7
Molecular classification: Ion channel, Non-selective cation channel, Transient receptor potential (TRP) channel, Receptor-activated cation channel

Overview

Transient receptor potential canonical 7 channel (TRPC7) is a member of the TRPC subfamily of ion channels. It forms a receptor-operated, non-selective cation channel permeable to Ca2+ and other cations. TRPC7 is activated downstream of receptors that couple to the phospholipase C pathway, primarily by diacylglycerol (DAG) independent of store depletion. It is expressed in many tissues, especially the brain, and functionally regulates processes such as calcium entry, cellular excitability, synaptic plasticity, pain transduction, and cell growth. Dysregulation of TRPC7 has been implicated in several pathologies, including seizure disorders, cancer, and aging-related diseases. Targeting TRPC7 offers potential for modulating calcium-dependent signaling but carries risks due to its widespread physiological roles.

Other names: Transient receptor potential cation channel subfamily C member 7Short transient receptor potential channel 7TRPC7 channel

Mechanism of action

Channel activation via direct binding of diacylglycerol (DAG), produced following stimulation of G protein-coupled or tyrosine kinase receptors and PLC (phospholipase C) pathway\nChannel function modulation by protein kinase C (PKC)-dependent phosphorylation and by calmodulin in response to elevated Ca2+

Biological functions

Calcium ion transmembrane transportRegulation of cytosolic calcium ion concentrationSignal transduction (via receptor-coupled phospholipase C pathways)Neuronal excitability and synaptic plasticityCell proliferationCell migrationInitiation of nociception (pain signaling)

Disease associations

Epilepsy/seizure generationCancer (including tumor growth and migration)Aging-associated tumorigenesis and skin agingPolycystic kidney diseaseCardiovascular disease

Safety considerations

Aberrant activation may contribute to seizure disorders and epilepsyEnhanced calcium influx can drive unwanted cell proliferation (e.g., in tumors or polycystic kidney disease)Targeting may impact cardiac and neurological function, given roles in excitability and plasticity

Interacting drugs

Specific drugs directly targeting TRPC7 in clinical use are not established; however, modulators include diacylglycerol analogs (such as OAG, 1-oleoyl-2-acetyl-sn-glycerol) and muscarinic agonists (e.g., carbachol) that activate the channel downstream of GPCR signaling

Biomarkers

None currently established for clinical use; expression or activity in neuronal or cancer tissue may serve as a potential experimental biomarker

Beyond the preview

Go deeper on Transient receptor potential canonical 7 channel (TRPC7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transient receptor potential canonical 7 channel (TRPC7).

Explore the full profile